99,295 Shares in Vericel Corporation $VCEL Bought by Jupiter Topco LLC

Jupiter Topco LLC bought a new stake in Vericel Corporation (NASDAQ:VCEL) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 99,295 shares of the biotechnology company’s stock, valued at approximately $4,417,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GW&K Investment Management LLC raised its position in Vericel by 22.5% during the fourth quarter. GW&K Investment Management LLC now owns 1,580,967 shares of the biotechnology company’s stock valued at $56,931,000 after purchasing an additional 290,795 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Vericel by 19.7% in the 1st quarter. Bank of America Corp DE now owns 1,098,771 shares of the biotechnology company’s stock valued at $35,347,000 after purchasing an additional 180,761 shares during the last quarter. Granite Investment Partners LLC increased its stake in shares of Vericel by 66.6% in the 1st quarter. Granite Investment Partners LLC now owns 120,236 shares of the biotechnology company’s stock valued at $3,868,000 after purchasing an additional 48,056 shares during the last quarter. Madison Asset Management LLC acquired a new position in shares of Vericel during the 2nd quarter worth $2,230,000. Finally, Lisanti Capital Growth LLC acquired a new position in shares of Vericel during the 2nd quarter worth $5,356,000.

Insider Buying and Selling at Vericel

In other Vericel news, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of Vericel stock in a transaction on Friday, June 26th. The shares were sold at an average price of $44.75, for a total transaction of $223,750.00. Following the transaction, the chief financial officer directly owned 16,009 shares of the company’s stock, valued at $716,402.75. The trade was a 23.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $40.21, for a total transaction of $603,150.00. Following the transaction, the insider owned 1,647 shares in the company, valued at approximately $66,225.87. This trade represents a 90.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 52,232 shares of company stock valued at $2,304,217 over the last ninety days. 7.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on VCEL. Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a report on Thursday, July 30th. Truist Financial reaffirmed a “buy” rating and set a $58.00 price target (up from $54.00) on shares of Vericel in a report on Friday, July 31st. TD Cowen upped their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Vericel in a research note on Tuesday, July 28th. Finally, Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Vericel has an average rating of “Moderate Buy” and an average price target of $58.40.

Vericel Price Performance

Shares of Vericel stock opened at $39.90 on Tuesday. Vericel Corporation has a one year low of $28.95 and a one year high of $49.32. The stock’s 50-day moving average is $44.90 and its 200 day moving average is $38.38. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of 84.90 and a beta of 1.06.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The company had revenue of $77.46 million for the quarter, compared to the consensus estimate of $72.70 million. During the same quarter in the previous year, the company earned ($0.01) EPS. Vericel’s quarterly revenue was up 22.5% compared to the same quarter last year. On average, sell-side analysts expect that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Vericel Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.